• Corpus ID: 26198474

Downregulation of NEK 11 is associated with drug resistance in ovarian cancer

  title={Downregulation of NEK 11 is associated with drug resistance in ovarian cancer},
  author={Xia Liu and Yutao Gao and Luo Yi and Jian Zhang and Li Li and Fuqiang Yin}
3 Citations

Figures and Tables from this paper

Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.

Complete analyses that including RT-qPCR, bioinformatics analysis and clinical data revealed an association of CKAP2, BCHE, CLDN10 and OVGP1 with drug resistance in OC, which might be prognostic factors as well as potential therapeutic targets in the treatment of OC.

Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.

A significant and consistent downregulation of TRPC1 in drug-resistant OC tissues/cells was determined using real-time quantitative polymerase chain reaction assays and the microarrays deposited in Oncomine and Gene Expression Omnibus profiles, providing the basis for further investigations of the drug-resistance-related functions of TR PC1 in OC and other forms of cancer.



ErbB2 overexpression in an ovarian cancer cell line confers sensitivity to the HSP90 inhibitor geldanamycin.

The data suggest that erbB2 status in ovarian cancr may contribute to chemosensitivity, in some cases leading to increased sensitivity but in other casesleading to resistance (as with cisplatin).

Cell cycle kinases in cancer.

Cell‐cycle inhibition and apoptosis induced by curcumin and cisplatin or oxaliplatin in human ovarian carcinoma cells

Epidemiological and experimental studies suggest that curcumin protects against cancer, not only because of its well‐known antioxidant properties, but also because it modulates intracellular signalling, which is related to cell proliferation and apoptosis.

Predicting gene ontology biological process from temporal gene expression patterns.

The aim of the present study was to generate hypotheses on the involvement of uncharacterized genes in biological processes. To this end, supervised learning was used to analyze microarray-derived

PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.

  • F. JankuJ. Wheler R. Kurzrock
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
A subset of patients with ovarian cancer with simultaneous PIK3CA and MAPK mutations responded to PI3K/AKT/mTOR inhibitors, suggesting that not all patients demonstrate resistance when the MAPK pathway is concomitantly activated.

Novel combination treatment for colorectal cancer using Nek2 siRNA and cisplatin

The results suggest that combination treatment using Nek2 siRNA and chemotherapeutic agents may be an effective therapeutic option for colorectal cancer.

Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.

The feasibility of obtaining gene expression profiles of xenografted tumor models as a result of drug exposure is shown, which might provide insights related to the drugs' action in vivo that will anticipate the response to treatment manifested by tumors and could be the basis for novel approaches to molecular pharmacodynamics.

Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death.

  • L. QiuW. Di Y. Wan
  • Biology, Chemistry
    International journal of oncology
  • 2005
It is concluded that paclitaxel transiently transactivates EGFR, leading to activation of cell survival factors, such as ERK and AKT, and expression of survivin, which are all inclusively accountable for ovarian cancer cell resistance to pac litaxel treatment.